Comparing the current results to its competitors, Codexis Inc reported Revenue decrease in the 2 quarter 2026 year on year by -2.69 %, slower than the combined decrease of the CDXS's competitors by -30.97 %, recorded in the same quarter.
Codexis inc , slower than the average decrease reported by the company's competitors of -41.03 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -41.03 %
Codexis Inc 's Comment on Competition and Industry Peers
The company utilizes its proprietary CodeEvolver technology platform to enhance enzyme performance. It protects its technology through patents and trade secrets to maintain exclusivity and cost advantages in supplying innovator and generic pharmaceutical manufacturers. As of December 31, 2025, the company holds approximately 1,600 active patents and pending applications related to enabling technologies and products in pharmaceutical, biotherapeutics, and oligonucleotide synthesis markets.
The competitive landscape includes early-stage competitors in enzymatic RNA manufacturing such as EnPlusOne Biosciences and a UK-based consortium led by the Centre for Process Innovation (CPI), which includes The University of Manchester, AstraZeneca plc, and Novartis. In the pharmaceutical biocatalysis market, competition comes from companies offering conventional non-enzymatic catalysts, alternative biocatalyst products and services, full-service contract development and manufacturing organizations (CDMOs), and in-house technologies within client companies. Competitive factors include price, product quality, biocatalyst performance, manufacturing yield, safety, environmental benefits, and speed of delivery. Additionally, pharmaceutical manufacturers using biocatalytic processes compete with those using conventional processes and manufacturers in regions with lower operating costs such as India and China.
despite revenue deterioration, Codexis Inc increased its market share in this segment. company increased its market share in this segment to approximately 0.53 %.
February 26, 2024
Codexis Inc., a notable enzyme engineering company, recently announced its exclusive global licensing agreement with Roche for the Company s newly engineered double-stranded DNA (dsDNA) ligase. This breakthrough technology is aimed at enhancing next-generation sequencing (NGS) library preparation and builds upon Codexis EvoT4 DNA ligase. The agreement signifies a significant strategic move for Codexis, especially considering the company s recent revenue decline in comparison to its competitors. Key Details of the Agreement:Under the terms of the agreement, Roche has acquired exclusive rights to Codexis dsDNA ligase for NGS library preparation, along with the existing EvoT4 DNA ligase license. In return, Co...
Biotechnology company Codexis had some significant news to share recently: the successful gram-scale synthesis using its ECO Synthesis Platform. This achievement, a significant milestone for the company, enables its engineers to model the manufacturing process for RNAi therapeutics. However, the shares of Codexis have been negatively impacted due to a sharp decline in revenues of about 73.09% in the third quarter of 2023, as compared to the same period the previous year. Notably, this revenue decrease is stark in contrast with an 8.12% revenue increase recorded by most of its competitors. Codexis groundbreaking ECO Synthesis platform exemplifies the commendable progress in the biotechnology and ph...
In a recent announcement, Codexis, Inc., a leading enzyme engineering company, revealed its participation in the 35th Annual Piper Sandler Healthcare Conference, which is scheduled to take place from November 28-30, 2023, in New York City. This event holds significant importance for Codexis as it provides a platform to showcase their innovative solutions within the healthcare industry. However, the company s recent financial performance raises concerns. Codexis Inc reported a substantial decline in revenue for the third quarter of 2023, with a staggering decrease of -73.09% compared to the previous year. This decline is significantly more drastic than the overall decrease of Codexis Inc s competitor...
Aptorum Group Limited's business model revolves around the development, commercialization, and sale of therapeutics and pharmaceutical products for various diseases and health conditions.
Becton Dickinson and Company operates a business model focused on developing and providing advanced medical technologies, including a diverse portfolio of medical devices and diagnostic products. Their strategy emphasizes innovation, quality, and strategic partnerships to enhance patient care and streamline healthcare processes across various settings.
Biomarin Pharmaceutical Inc operates as a biotechnology company, specializing in the development and commercialization of innovative therapies for rare genetic diseases. Their business model revolves around conducting extensive research and development to identify and address unmet medical needs, manufacturing and marketing their approved products, and collaborating with strategic partners to maximize the reach and impact of their therapies worldwide. By focusing on rare diseases, Biomarin leverages their expertise to provide targeted and innovative treatments, ultimately improving the lives of patients in need.
DuPont De Nemours Inc operates as a diversified science and technology company, leveraging advanced materials and innovative solutions to serve multiple industries such as agriculture, electronics, transportation, and healthcare. The companys business model emphasizes sustainability and innovation, aiming to meet the evolving needs of its customers while addressing global challenges.
Mdb Capital Holdings LLC operates as a venture capital firm, investing in companies primarily in the technology sector. They provide financial resources and expertise to startups and early-stage companies in exchange for equity ownership. Their business model focuses on identifying and nurturing promising innovations, aiming to generate substantial returns on investments through successful exits or acquisitions.
Sources:
Codexis inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Codexis inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
